No Data
No Data
H.C. Wainwright Initiates Inovio Pharmaceuticals(INO.US) With Hold Rating, Announces Target Price $3
RBC Capital Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $5
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Inovio Aims for INO-3107 Regulatory Submission by Mid-2025 While Addressing Key Manufacturing Issues
Express News | HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target
Inovio Pharmaceuticals: Hold Rating Amid Promising Developments and Financial Challenges